Clinical Trial Update: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports on the efficacy and safety of GSK4527226 (AL101) in participants with early Alzheimer's disease. The study is currently listed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GSK4527226 (AL101) (GSK4527226)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING